Matza Louis S, Johnston Joseph A, Faries Douglas E, Malley Karen G, Brod Meryl
Center for Health Outcomes Research at UBC, 7101 Wisconsin Avenue, Suite 600, Bethesda, MD 20814, USA.
Qual Life Res. 2007 Nov;16(9):1511-20. doi: 10.1007/s11136-007-9254-9. Epub 2007 Sep 12.
This study examined responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL), which was developed to assess health-related quality of life (HRQL) among adults with attention-deficit/hyperactivity disorder (ADHD).
Adults with ADHD completed the AAQoL, Conners' Adult ADHD Rating Scale (CAARS), SF-36, and Endicott Work Productivity Scale (EWPS) at baseline and week 8 of a randomized, placebo-controlled trial of atomoxetine. Clinicians rated symptom severity and improvement (CGI-ADHD-S, CGI-ADHD-I). Responsiveness was examined through effect sizes and association with change in the measures listed previously (Spearman correlations, GLMs).
Analyses included 328 patients (58.8% male; mean age = 36.9 years). All AAQoL scales reflected significant improvement from baseline to week 8 (P < 0.0001). AAQoL change scores were significantly correlated with change in the CGI-ADHD-S (r = -0.37 to -0.50), EWPS (r = -0.43 to -0.63), and CAARS (r = -0.35 to -0.62) (all P < 0.001). AAQoL change scores significantly discriminated among patients with various levels of symptom improvement. AAQoL effect sizes (-0.67 to -1.11) were larger than effect sizes for the SF-36 (0.15 to -0.39).
The AAQoL was responsive to change in symptoms of ADHD, and it appears to be a useful outcome measure for treatments of ADHD in adults.
本研究检验了成人注意力缺陷多动障碍生活质量量表（AAQoL）的反应性，该量表旨在评估注意力缺陷多动障碍（ADHD）成人患者的健康相关生活质量（HRQL）。
患有ADHD的成人在基线期以及托莫西汀随机、安慰剂对照试验的第8周完成AAQoL、康纳斯成人ADHD评定量表（CAARS）、SF-36和恩迪科特工作效率量表（EWPS）。临床医生对症状严重程度和改善情况进行评分（CGI-ADHD-S、CGI-ADHD-I）。通过效应量以及与之前列出的测量指标变化的相关性（斯皮尔曼相关性、广义线性模型）来检验反应性。
分析纳入了328例患者（58.8%为男性；平均年龄 = 36.9岁）。所有AAQoL量表均显示从基线期到第8周有显著改善（P < 0.0001）。AAQoL变化分数与CGI-ADHD-S（r = -0.37至-0.50）、EWPS（r = -0.43至-0.63）和CAARS（r = -0.35至-0.62）的变化显著相关（均P < 0.001）。AAQoL变化分数在不同症状改善水平的患者中具有显著差异。AAQoL效应量（-0.67至-1.11）大于SF-36的效应量（0.15至-0.39）。
AAQoL对ADHD症状变化有反应，似乎是成人ADHD治疗的一个有用的结局指标。
